Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs
Faculty of Pharmaceutical, Biomedical and Veterinary Sciences. Pharmacy
Journal of veterinary internal medicine. - Philadelphia, Pa
, p. 929-934
University of Antwerp
Background In congestive heart failure (HF), plasma B-type natriuretic peptide (BNP) seems devoid of biological effectiveness. BNP132 could be truncated into BNP332 by dipeptidyl peptidase IV (DPP4), and BNP332 has reduced biological activities. Hypothesis Increased DPP4 activity is associated with pathophysiology of HF. Animals One hundred twenty-eight client-owned dogs and 9 experimental Beagles from the Clinical Veterinary Unit of the University of Liège. Methods We prospectively measured plasma DPP4 activity in 5 groups of dogs: normal growing dogs (n = 21), normal adult dogs (n = 60), healthy Beagle (n = 9), dogs with myxomatous mitral valve disease (n = 35), and dogs with dilated cardiomyopathy (n = 12). The final diagnosis and the severity of HF were determined by Doppler echocardiography. Plasma DPP4 activity was measured kinetically by a fluorimetric method. Results In growing dogs, DPP4 activity was higher than in adults (P < .001) and inversely correlated with age (r = −0.57, P < .01). In adults, DPP4 activity increased linearly with body weight (r = 0.39, P < .01), but there was no influence of age or sex. No effect of the circadian rhythm was noted. DPP4 activity was significantly higher in HF ISACHC I (16.3 ± 1.14 U/L) compared with healthy adults (12.4 ± 0.65 U/L, P < .05) and HF ISACHC III (11.0 ± 1.50 U/L, P < .05). Mean DPP4 activity in ISACHC II was 15.1 ± 1.4 U/L. Conclusion and Clinical Importance We did not find evidence that plasma DPP4 activity is responsible for the BNP resistance in overt congestive HF, but it may be implicated in early stages.